Office for Technology Commercialization

Analgesics for Inflammatory Pain

Technology #20130119

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
MorphineInflammatory Pain
Philip S. Portoghese, PhD
Distinguished Professor, Medicinal Chemistry, College of Pharmacy
External Link (
Eyup Akgun, PhD
Research Associate Professor, Medicinal Chemistry, College of Pharmacy
External Link (
Managed By
Raj Udupa
Technology Licensing Officer 612-624-3966
Patent Protection

US Patent Pending US-2015-0374836
Files and Attachments
Non-Confidential Summary [PDF]

More Potent Analgesics for Inflammatory Pain

An analgesic has been synthesized that’s been proven to reduce post-operative pain, neuropathic pain, and pain from burns, spinal injuries and terminal cancers. There was no perceivable tolerance displayed in mouse model in vivo studies, while inflammatory pain was effectively reduced. This synthetic analgesic is more potent than other opioid analgesics due to simultaneous activation of opioid pathways and blockage of hyperalgesia caused by metabotropic glutamate-5 receptor signaling. The analgesic has widespread applications in inflammation reduction and pain treatment.

MN-IP Try and Buy
This technology is available via a standard negotiated license agreement. Contact Raj Udupa for specific details.

Limitations of Morphine and Currently Available Pain Killers

Current pain treatments rely upon analgesics such as morphine, which can be habit forming and develop tolerance by the body, requiring increased dosages and extended use in order to be effective. Morphine and synthetic opioids are marginally effective or become ineffective, particularly upon chronic administration, in treating certain spinal injuries, neuropathic pain, burns, inflammation, post-operative pain, and pain caused by terminal cancers. There is a prevalent need for the development of potent, effective analgesics that are able to treat these injuries and illnesses without dependency and tolerance.


  • The body does not develop tolerance to the drug, making it a viable alternative to opioids that require increased doses over time
  • Able to reduce and inhibit neuropathic pain, post-operative pain, and pain in burns, spinal injuries and inflammation not usually treatable with morphine or other opioids
  • Synthetic analgesic is more potent and effective than other opioid analgesics

Fulfillment Details Licensee will receive rights to practice the intellectual property (patent application) for the purposes of developing and manufacturing a commercial product.

Phase of Development In vivo animal studies